Valbonne, France, November 7, 2014. – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London. The presentation is scheduled for Thursday, November 13, 2014 at 10:30 a.m. at 30 Euston Square, London, NW1 2FB, United Kingdom.
Damian Marron will provide to investors and analysts an overview of TxCell, its clinical developments and its plans. He will present details on TxCell’s unique versatile innovative technological platform, ASTrIA and the company’s portfolio of economically viable personalized T cell immunotherapies for severe chronic inflammatory and autoimmune diseases. This includes TxCell’s lead product for refractory Crohn’s disease, Ovasave(R), which is due to start a phase IIb study shortly. It also includes TxCell’s second product candidate, Col-Treg, for the rare eye disease, autoimmune uveitis. A phase I/II proof of principle clinical trial for Col-Treg is planned to start in H1 2015.
The 2nd Annual EU Advanced Therapies Investor Day is organized by the Alliance for Regenerative Medicine (ARM). The day will be co-hosted by GE Healthcare, Cell Therapy Catapult and Bryan Garnier, and held in partnership with the BioIndustry Association (BIA). The event will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector. There will also be presentations by 15 selected leading European and International advanced therapies companies, including TxCell.
“TxCell has continued to develop rapidly since its IPO in April of this year. We are in a strong position, with one of the most advanced, innovative T-cell immunotherapy product pipelines, backed up by an extensive patent portfolio, a partnership with a major pharmaceutical company, a GMP validated manufacturing process and a robust discovery platform,” said Damian Marron, CEO TxCell. “Hence it is very important to inform and update investors at the EU Advanced Therapies Investor Day who have unique insight into investment hypotheses for advanced therapies-based treatments.”
TxCell is developing innovative, economically viable, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell uses a unique and proprietary ASTrIA technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has completed a phase I/IIa study of its lead product candidate, Ovasave(R) in refractory Crohn’s disease patients and has reported good tolerability and positive clinical efficacy. The company plans to initiate a phase IIb study in the same patient population. TxCell has a strategic partnership for Ovasave with the Swiss company Ferring International Center. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France’s National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 49 employees based at its headquarters and at its manufacturing site in Besançon.
For more information, please visit www.txcell.com
Practical Information about TxCell shares:
ISIN code FR0010127662
Ticker code TXCL
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations.
To learn more about ARM or to become a member, visit www.alliancerm.org.
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.